drugset / Trial / NCT00721955

Staccato Loxapine in Agitated Patients With Bipolar Disorder

NCT00721955

Phase 3 Completed 314 enrolled Alexza Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in bipolar 1 disorder patients.

Timeline

Start
2008-07
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject loxapine Small molecule 5 mg Inhaled
Subject loxapine Small molecule 10 mg Inhaled

Indications